Cellectis SA
PAR:ALCLS

Watchlist Manager
Cellectis SA Logo
Cellectis SA
PAR:ALCLS
Watchlist
Price: 4.015 EUR -1.35% Market Closed
Market Cap: 289.4m EUR

Cellectis SA
Cost of Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cellectis SA
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cellectis SA
PAR:ALCLS
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cost of Revenue
-€148.8m
CAGR 3-Years
23%
CAGR 5-Years
-25%
CAGR 10-Years
-15%
Nanobiotix SA
PAR:NANO
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cost of Revenue
-€85.9m
CAGR 3-Years
-1%
CAGR 5-Years
-10%
CAGR 10-Years
-16%
No Stocks Found

Cellectis SA
Glance View

Market Cap
290.4m EUR
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

ALCLS Intrinsic Value
2.473 EUR
Overvaluation 38%
Intrinsic Value
Price

See Also

Back to Top